The antinuclear antibody (ANA) test is one of the most commonly ordered screening tests in rheumatology — used to evaluate for autoimmune conditions including systemic lupus erythematosus, Sjögren’s syndrome, mixed connective tissue disease, scleroderma, and polymyositis. A positive ANA result prompts further specific autoantibody testing, while a negative result is generally considered reassuring. However, a false negative ANA test — one that returns negative despite the presence of genuine autoimmune disease — can occur, and specific medications are among the most clinically important causes.
How Medications Can Suppress ANA Results
The mechanisms by which medications produce false negative ANA results are multiple and not fully elucidated. The most significant category is immunosuppressive drugs — agents that reduce immune system activity as their primary therapeutic mechanism. By suppressing the B-cell function responsible for producing autoantibodies and reducing the overall inflammatory activity that drives autoantibody production, immunosuppressives can reduce circulating ANA levels below the detection threshold even in individuals with established autoimmune disease. Corticosteroids — prednisone, prednisolone, dexamethasone — are the most commonly implicated agents. High-dose or prolonged corticosteroid use can suppress ANA titres significantly. Clinicians ordering ANA testing ideally time it before corticosteroid initiation or during periods of lower dosing when possible, but this is not always clinically feasible.
Disease-Modifying Antirheumatic Drugs
Methotrexate, hydroxychloroquine, azathioprine, mycophenolate mofetil, and leflunomide — the conventional DMARDs used in rheumatoid arthritis and other autoimmune conditions — all reduce immune system activity in ways that can suppress autoantibody production. For patients already established on these agents when ANA testing is ordered, the possibility of a suppressed result must be factored into interpretation. Biologic DMARDs — including the anti-TNF agents (adalimumab, etanercept, infliximab), rituximab, and abatacept — produce more targeted immunosuppression that may also affect ANA results, though the specific effects on ANA titres vary between mechanisms and individual agents.
Other Medications With Reported Effects
Beyond immunosuppressives, certain medications have been associated with altered ANA results through different mechanisms. Procainamide and hydralazine are well-known causes of drug-induced lupus — a condition that produces positive ANA and lupus-like symptoms that resolve when the medication is discontinued. In this context, the medication produces a true positive rather than a false negative. However, the broader category of questioning what medications can cause a false negative ANA test extends to anticonvulsants including carbamazepine and phenytoin, which have complex immunomodulatory effects.
The Interpretation Context
ANA testing interpretation always requires clinical context — the specific titre, the pattern reported (homogeneous, speckled, nucleolar, centromere), the clinical presentation, and the medication history. A negative ANA in a patient on high-dose corticosteroids for an established autoimmune condition should not be interpreted as evidence of disease remission without corroborating clinical and laboratory data. Comprehensive information on autoimmune testing, what ANA results mean in different clinical contexts, and how follow-up specific autoantibody testing is structured is available through resources like mymedicallab.net — helping patients and caregivers understand complex laboratory findings in accessible, accurate language.